BioMarin Pharmaceutical Conference Call Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Date**: March 09, 2026 - **Key Speakers**: Brian Mueller (CFO), Cristin Hubbard (CCO) Key Points Industry and Company Performance - BioMarin reported a **13% revenue growth** in 2025, with the Skeletal Conditions unit (including VOXZOGO) growing by **26%** and Enzyme Therapies by **9%** [4][5] - The company anticipates **high single-digit growth** for both Skeletal Conditions and Enzyme Therapies in 2026 [4] Strategic Growth Pillars - BioMarin's corporate strategy is built on three pillars: **growth, innovation, and value commitment** [4] - The company is preparing for the **Amicus acquisition** in Q2 2026, which is expected to enhance its portfolio with two high-growth products in rare genetic conditions [5] Product Pipeline and Innovations - Recent approval of **PALYNZIQ** for adolescents and upcoming **Phase 3 data readouts** for VOXZOGO in hypochondroplasia and BMN 401 for ENPP1 deficiency [5][6] - Ongoing development of **BMN 351** for Duchenne muscular dystrophy and **BMN 333**, a long-acting CNP for achondroplasia [6] Market Dynamics and Patient Retention - BioMarin is focused on patient retention for VOXZOGO, emphasizing that **efficacy and safety** are key factors influencing caregivers' decisions to switch therapies [10][11] - Approximately **two-thirds** of KOLs and caregivers believe that switching therapies is unlikely if patients are doing well on current treatments [11] Achondroplasia Market Insights - The company is working to build a broader health narrative around achondroplasia beyond just growth, focusing on overall health benefits [12][14] - BioMarin has a long history with VOXZOGO, having started its development program over **15 years ago**, and is now filing for full approval based on long-term data [20] Hypochondroplasia Opportunity - The Phase 3 trial for hypochondroplasia is expected to yield data in the **first half of 2026**, with strong enrollment indicating market excitement [25][26] - The company is focusing on **disease awareness** and improving the diagnosis journey for hypochondroplasia patients [28][30] Amicus Acquisition and Market Expansion - The acquisition of Amicus is expected to enhance BioMarin's market presence, with **Galafold** currently available in **40 countries** and BioMarin operating in **80** [38] - The integration of Amicus products is anticipated to unlock additional value through deeper market penetration and improved diagnosis efforts [39][43] Financial Projections - The Amicus acquisition may be slightly dilutive in **2026** but is expected to be accretive in the first 12 months and substantially accretive thereafter [45] - BioMarin expects **VOXZOGO revenues** in the second half of 2026 to exceed the first half, primarily due to international order timing [64][66] Manufacturing and Operational Strategy - BioMarin is recognized for its high-quality manufacturing capabilities and plans to leverage these skills for Amicus products, particularly POMP [51][53] Clinical Data and Future Expectations - Upcoming data cuts for **BMN 351** and pivotal Phase 3 data for **ENPP1 deficiency** are anticipated, with a focus on patient diagnosis and treatment initiation [54][57] Conclusion BioMarin Pharmaceutical is positioned for continued growth through strategic acquisitions, a robust product pipeline, and a commitment to enhancing patient care in rare genetic conditions. The company is focused on leveraging its manufacturing expertise and expanding its market presence while maintaining a strong emphasis on patient retention and treatment efficacy.

Financial Data and Key Metrics Changes - Total revenues for 2025 grew by 13% to a record $3.22 billion, driven by a 9% increase in enzyme therapies revenue and a 26% rise in Voxzogo revenues [6][11] - Fourth quarter revenues reached $875 million, representing a 17% year-over-year growth, with Voxzogo delivering 31% growth and enzyme therapies achieving 13% growth [11][12] - Full-year 2025 non-GAAP diluted earnings per share was reported at $3.15, with underlying business earnings per share growing by approximately 34% [14][15] Business Line Data and Key Metrics Changes - Enzyme therapies revenue increased by 9% year-over-year for 2025, with Palynziq growing by 22% and Vimizim by 7% [13][21] - Voxzogo revenue for 2025 totaled $927 million, with 73% generated outside the United States, highlighting the company's global reach [12][13] - Palynziq is expected to remain a primary growth driver in 2026, supported by an anticipated adolescent label expansion [22] Market Data and Key Metrics Changes - Voxzogo achieved 26% year-over-year growth in 2025, with over 5,000 children treated globally by year-end [23] - The company is focusing on expanding its market presence in newly launched countries and increasing penetration in existing markets, particularly among children under two years of age [24][27] - Approximately 75% of Voxzogo's total revenues are generated from countries outside the United States, emphasizing the importance of international markets [26] Company Strategy and Development Direction - The company plans to expand its therapeutic and commercial reach through acquisitions, including Inozyme and Amicus, which will enhance its enzyme therapies portfolio [7][8] - BioMarin aims to build on Voxzogo's leadership in achondroplasia and expand its indications to include hypochondroplasia [9] - The company is actively engaged in business development targeting pipeline assets to drive long-term growth [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain revenue growth and profitability, with expectations for high single-digit growth in enzyme therapies and Voxzogo in 2026 [17][19] - The company anticipates total revenues for 2026 to be in the range of $3.325 billion to $3.425 billion, excluding contributions from the Amicus acquisition [18] - Management highlighted the importance of early treatment for patients and the long-term benefits of Voxzogo, supported by extensive safety and efficacy data [39][40] Other Important Information - The company recorded approximately $240 million in special items during Q4 due to the strategic decision to withdraw Roctavian from the market [14] - BioMarin secured approximately $3.7 billion in debt financing to support the Amicus acquisition, reflecting confidence in its business outlook [15][16] Q&A Session Summary Question: Dynamics in the achondroplasia market with new oral therapies - Management noted that Voxzogo has extensive supporting evidence and long-term safety data, which may influence patient and physician decisions regarding treatment options [36][37] Question: Factors driving patient switching decisions - Management indicated that efficacy and safety are the highest priorities for patients, with long-term data playing a crucial role in the decision to switch therapies [51] Question: Expected timing for data readouts from the phase II CANOPY study - Management anticipates data in the 2027 timeframe for the CANOPY study, which includes hypochondroplasia [78] Question: Voxzogo guidance and market access considerations - Management is being cautious regarding routine market access negotiations, which may impact revenue growth but also present opportunities for broader access [81]

Financial Data and Key Metrics Changes - In 2025, total revenues grew by 13% to a record $3.22 billion, driven by a 9% increase in enzyme therapies revenue and a 26% rise in Voxzogo revenues [4][10] - For Q4 2025, total revenues reached $875 million, representing a 17% year-over-year growth, with Voxzogo delivering 31% growth and enzyme therapies achieving 13% growth [10][11] - Full-year 2025 non-GAAP diluted earnings per share was reported at $3.15, with underlying business earnings per share growing by approximately 34% [12][13] Business Line Data and Key Metrics Changes - Enzyme therapies revenue for 2025 increased by 9% year-over-year, led by 22% growth for Palynziq and 7% growth for Vimizim [11][12] - Voxzogo revenue for 2025 totaled $927 million, with approximately 73% generated outside the United States, highlighting BioMarin's global reach [11][12] - Palynziq is expected to remain the primary growth driver in the enzyme therapy portfolio, supported by an anticipated adolescent label expansion [20] Market Data and Key Metrics Changes - Voxzogo achieved 26% year-over-year growth in 2025, with over 5,000 children treated worldwide by the end of the year [21] - The company anticipates continued high patient demand across both enzyme therapies and Voxzogo in 2026, resulting in high single-digit growth rates [15][16] - Approximately 75% of Voxzogo's total revenues are generated from countries outside the United States, indicating a strong international market presence [23] Company Strategy and Development Direction - BioMarin plans to expand its therapeutic and commercial reach through acquisitions, including Inozyme and Amicus, which will enhance its enzyme therapies portfolio [5][6] - The company is focused on pipeline expansion and innovation, with several anticipated data readouts and regulatory activities planned for 2026 [26][29] - BioMarin aims to solidify its revenue growth potential and transform its cost structure to achieve a strong operating margin profile [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue expanding Voxzogo's market presence and achieving blockbuster status [9][10] - The company anticipates that integrating Amicus's products will significantly enhance its 2026 outlook and accelerate revenue growth through the 2030s [9][16] - Management highlighted the importance of early treatment for patients and the long-term benefits of Voxzogo, supported by extensive safety and efficacy data [38][46] Other Important Information - BioMarin made a strategic decision to withdraw Roctavian from the market, resulting in approximately $240 million in special items recorded during Q4 [12] - The company secured approximately $3.7 billion in debt financing to support the Amicus acquisition, reflecting confidence in its business and financial outlook [13][14] Q&A Session Summary Question: Dynamics in the achondroplasia market with new oral therapies - Management noted that Voxzogo has extensive supporting evidence and long-term safety data, which may influence patient and physician decisions regarding treatment options [33][34] Question: Factors driving patient switching decisions - Management indicated that efficacy and safety are the highest priorities for patients, with long-term data playing a crucial role in the decision to switch therapies [46][47] Question: Expected timing for data readouts from the phase 2 CANOPY study - Management anticipates data in the 2027 timeframe for the CANOPY study, which includes hypochondroplasia [74] Question: Voxzogo guidance and market access negotiations - Management is being cautious regarding routine market access negotiations, which may impact pricing but also provide opportunities for broader patient access [77][78]

Core Insights - BioMarin Pharmaceutical is targeting a preliminary revenue of $3.2 billion for 2025, with Voxzogo expected to contribute $920 million, reflecting a strong performance and a projected 27% year-over-year growth in Q4 [3][6] - The company is focusing on expanding Voxzogo's market presence and enhancing its enzyme therapies portfolio, alongside the strategic acquisition of Amicus, valued at $4.8 billion, which is expected to diversify and accelerate revenue growth [7][8] Revenue and Growth Projections - BioMarin anticipates Voxzogo's growth in achondroplasia will be supported by new country launches and deeper market penetration, particularly emphasizing early treatment decisions for infants [2][6] - The acquisition of Amicus is expected to be accretive within 12 months post-close and substantially accretive starting in 2027, with confidence in outperforming previous growth expectations for enzyme therapies [8][7] Strategic Focus and Pipeline Development - The company's strategy is built on three pillars: innovation, growth, and a value commitment, prioritizing pipeline programs with transformative potential, including BMN 333 and BMN 351 [5][6] - BioMarin plans to accelerate revenue through geographic expansion of Voxzogo and potential label expansions for other therapies, including Palynziq [4][6] Clinical and Regulatory Catalysts - BioMarin is preparing to file for full approval of Voxzogo with the FDA, leveraging extensive safety data and additional efficacy endpoints [11] - Upcoming regulatory actions include an FDA PDUFA date for Palynziq's adolescent label expansion and significant data readouts for BMN 351 and BMN 333 [12][10][13] Competitive Dynamics and Intellectual Property Strategy - The company is committed to defending its intellectual property for Voxzogo, including seeking orphan drug exclusivity and engaging in ongoing litigation to protect its market position [15][16] - BioMarin views BMN 333 as a potential long-term game changer for achondroplasia, based on its promising exposure profile [16]

BioMarin Pharmaceutical FY Conference Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Event**: FY Conference held on January 12, 2026 - **CEO**: Alexander Hardy Key Industry Insights - BioMarin is a leader in genetically defined conditions with a strong track record of innovation, having six first-in-disease treatments and many best-in-disease treatments [6][7] - The company operates in 80 countries and has significant R&D capabilities and in-house manufacturing [6][7] Core Financial Highlights - Preliminary revenue for 2025 is projected at **$3.2 billion**, with a **15% CAGR** over the last two years [9][21] - Voxzogo, a treatment for achondroplasia, is expected to generate **$920 million** in revenue for 2025, reflecting a **27% year-over-year growth** [19][21] Strategic Pillars 1. **Innovation**: Focus on transformative potential in the pipeline, with key assets like 333 and 351 showing promise [8][12] 2. **Growth**: Significant growth rates driven by enzyme therapies and the expansion of Voxzogo into new indications and countries [9][10] 3. **Value Commitment**: Cost transformation efforts have identified **$500 million** in cost reductions, enhancing profitability and cash flow [10] Amicus Acquisition - BioMarin announced the acquisition of Amicus for an equity value of **$4.8 billion**, which is expected to enhance revenue growth and diversify the revenue base [14][15] - Key products from Amicus include: - **Galafold** for Fabry disease, currently available in **40 countries**, with plans to expand to BioMarin's **80-country footprint** [16][17] - **Pombiliti** for Pompe disease, currently reimbursed in **15 countries**, with potential for significant growth [18] Pipeline and R&D Updates - Upcoming catalysts include: - Filing for full approval of Voxzogo in achondroplasia [12][34] - Two phase 3 data readouts and label expansions expected within the year [12][24] - BMN 351 for Duchenne muscular dystrophy showing promising early results [24][25] - BMN 333 for achondroplasia demonstrating over **13-fold** increase in free CNP exposure [28] Market Position and Competition - BioMarin is focused on defending its market position for Voxzogo against potential competitors by leveraging its established safety profile and efficacy data [49][50] - The company has petitioned for orphan drug exclusivity to delay the approval of competing products for **three more years** [49] Future Outlook - BioMarin aims for sustained double-digit CAGR growth into the 2030s, supported by the integration of Amicus products and ongoing pipeline developments [22][37] - The company is optimistic about its ability to reach more patients and enhance treatment options through its expanded portfolio [15][51] Additional Notes - The adherence rate for Voxzogo is approximately **90%**, indicating strong patient retention [45] - The company emphasizes the importance of early diagnosis and treatment in achondroplasia, which is expected to drive future growth [39][40]

Group 1 - BioMarin Pharmaceutical Inc. is recognized as one of the best biotech stocks to buy according to Wall Street analysts, with a focus on developing therapies for severe, life-threatening rare genetic diseases [1][4] - The company is currently implementing a $500 million cost transformation program, which is about two-thirds complete, aiming for a 40% non-GAAP operating margin in the next year, an increase from 19% in 2023 [1] - BioMarin is concentrating on genetically defined conditions with few competitors, highlighting the global rollout of Voxogo in 55 countries and the growth of Palynziq at over 20% annually [2] Group 2 - Analysts at Leerink Partners downgraded BioMarin's stock to Market Perform from Outperform and reduced the price target to $60 from $82, while acknowledging the company's restructuring efforts [3] - The restructuring includes labor force reduction, pipeline reorganization, and the discontinuation of the Roctavian program, alongside the acquisition of Inozyme, which is expected to drive future growth [3] - The company is focused on innovation and speeding up the development of its pipeline to create value for shareholders, despite facing regulatory and competitive pressures [2][3]

Summary of BioMarin Pharmaceutical Conference Call Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Event**: 2025 Conference on November 18, 2025 Key Points Company Strategy and Financials - BioMarin's CEO highlighted a two-year milestone, reflecting on significant changes and a focus on execution [2] - The company has reorganized its strategy around three pillars: growth from the existing portfolio, innovation through its pipeline, and value commitment to enhance profitability and cash flow [2] - A cost transformation initiative has identified $500 million in potential savings, which has been directed towards improving cash flow and strengthening the balance sheet [3][4] Pipeline Developments - Upcoming pipeline readouts include: - **BMN 351** for Duchenne muscular dystrophy, with top-line results expected by the end of 2025 [3] - **Voxogo** for hypochondroplasia, with Phase 3 data readout anticipated early next year [3] - **Palynziq** for adolescents, with an FDA action date set for February 28, 2026, and current growth exceeding 20% [4] Business Development (BD) Environment - The company has a robust BD function aimed at supplementing internal innovation, focusing on genetically defined conditions with relatively low competitive pressure [6][9] - BioMarin is strategically positioned to leverage its geographic footprint, with 68% of patients for achondroplasia located outside the U.S. and Europe [10] Market Dynamics and Competition - The company believes that Voxogo will continue to grow, with significant opportunities in both achondroplasia and hypochondroplasia markets [19] - Concerns about competition are acknowledged, but the company maintains confidence in Voxogo's market position and patient retention due to established safety and efficacy [26][28] Regulatory and Approval Considerations - Discussions around the potential for full approval of Voxogo are ongoing, with emphasis on presenting comprehensive data to regulators [34] - The company is also engaged in litigation regarding intellectual property, which may impact market competition [38] Hypochondroplasia Insights - The addressable market for hypochondroplasia is estimated at 14,000 patients, with a focus on creating awareness and understanding of the disease [41] - The study for hypochondroplasia is powered to look for an average growth height velocity of 1.5 cm per year, with expectations based on previous data showing higher growth rates [44] Conclusion - BioMarin is positioned for growth through strategic investments, a strong pipeline, and a focus on genetically defined conditions, while navigating competitive and regulatory landscapes [2][4][19][34]

Core Viewpoint - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is recognized as a promising growth stock with a maintained Buy rating and a price target of $104 by analysts [1][2]. Group 1: Market Position and Growth Potential - The company has a strong market position and significant growth potential, particularly through the international expansion of its product Voxzogo, which has demonstrated revenue growth [2]. - Management is expected to continue expanding Voxzogo into additional countries, which is identified as a key driver for the company's growth [2]. Group 2: Pipeline and Future Catalysts - BioMarin has a promising pipeline, with BMN 351 and BMN 333 highlighted as potential catalysts for future growth [3]. - The company's ability to maintain its leadership in skeletal dysplasias, despite challenges, further strengthens its market position [3]. Group 3: Company Overview - BioMarin Pharmaceutical Inc. is an international biopharmaceutical company focused on developing and commercializing targeted therapies for rare genetic conditions [4].

Core Insights - BioMarin Pharmaceutical (BMRN) reported Q2 2025 adjusted EPS of $1.44, exceeding the Zacks Consensus Estimate of $1.03, with a 50% year-over-year increase driven by higher product sales and lower operating expenses [1][9] - Total revenues reached $825.4 million, reflecting a 16% year-over-year increase, surpassing the Zacks Consensus Estimate of $766.2 million [1][9] Revenue Breakdown - Product revenues totaled $813 million, a 16% year-over-year increase, primarily due to higher sales from Voxzogo, Palynziq, Vimizim, and Aldurazyme, partially offset by lower Kuvan sales [2] - Voxzogo generated $221 million in sales, up 20% year over year, exceeding the Zacks Consensus Estimate of $219 million [3] - Enzyme Therapies sales rose 15% year over year to $555 million, driven by increased patient demand and large government orders [4] - Palynziq injection sales increased 20% year over year to $106 million, surpassing both the Zacks Consensus Estimate and internal model estimates [5] - Vimizim sales rose 21% year over year to $215 million, beating both the Zacks Consensus Estimate and internal model estimates [6] - Aldurazyme sales totaled $56 million, up 44% year over year, attributed to favorable order fulfillment timing [6] Financial Guidance - BioMarin revised its 2025 revenue forecast to $3.13-$3.20 billion, reflecting an 11% year-over-year increase at the midpoint [11] - Adjusted EPS guidance was raised to $4.40-$4.55, indicating a 27% growth over the previous year at the midpoint [14] - The company expects Voxzogo sales to be between $900-$935 million, with higher revenues anticipated in the second half of the year [12] Pipeline Developments - The acquisition of Inozyme added BMN 401, an investigational enzyme replacement therapy for rare disorders, with interim results expected in early 2026 [18][19] - BioMarin is advancing its CANOPY clinical program for Voxzogo, targeting additional indications with data expected in 2026 [22] - BMN 333, a long-acting formulation of CNP, is set to enter a phase II/III study in 2026, aiming for a potential launch in 2030 [23] - The company plans to file for expanded use of Palynziq in adolescents based on positive late-stage study results [21]

Financial Data and Key Metrics Changes - BioMarin reported a revenue growth of 15% in Q1 2025, totaling $745 million compared to the same period last year [12] - Non-GAAP earnings per share reached $1.13, representing a 59% year-over-year increase, indicating significant profitability expansion [5][19] - Non-GAAP operating margin expanded to 35.7%, an increase of 11.9 percentage points year-over-year [15] Business Line Data and Key Metrics Changes - Voxzogo's global revenue reached $214 million, a 40% increase year-over-year, continuing its strong growth trajectory since approval [13] - Revenue from the Enzyme Therapies business unit grew 8% year-over-year to $484 million, with Palynziq contributing a 22% increase compared to Q1 2024 [13][22] - Full-year revenue expectations for Voxzogo are between $900 million and $950 million, representing a 26% growth at the midpoint [14] Market Data and Key Metrics Changes - Approximately two-thirds of BioMarin's total revenues originate from outside the United States, providing insulation from U.S. macroeconomic conditions [7][9] - The company is analyzing potential exposure to pharmaceutical tariffs and believes its global revenue base offers protection against such impacts [8][9] Company Strategy and Development Direction - BioMarin is focused on implementing changes to its strategy and operating model announced in September 2024, aiming for record full-year performance in 2025 [6][11] - The company is advancing its innovation strategy, with pivotal studies for Voxzogo and plans for new product applications in the second half of 2025 [10][24] - BioMarin aims to leverage its established global capabilities to support growth and innovation, particularly in rare disease treatments [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in BioMarin's ability to navigate market uncertainties due to its focus on rare conditions and strong cash generation [6][7] - The company anticipates continued strong performance and innovation in the coming quarters, supported by its strategic transformation [11][19] Other Important Information - Non-GAAP R&D expenses were $147 million, lower than the same quarter in 2024, reflecting a reprioritization of R&D efforts [14] - Non-GAAP SG&A expenses decreased to $183 million due to cost transformation initiatives [15] Q&A Session Summary Question: Will Q2 revenue for Voxzogo decline? - Management indicated that while Q1 showed growth, Q2 revenue may appear flat due to global order dynamics, with expectations for stronger growth in the second half of the year [35][36] Question: How could potential U.S. tariffs impact financials? - Management stated that current guidance includes modest impacts from existing tariffs, but they are modeling various scenarios for potential future tariffs [36][37] Question: What strategies are being implemented to drive further adoption of Voxzogo? - The company is focusing on increasing awareness and expanding the prescriber base, particularly among pediatric endocrinologists, to drive adoption across all age groups [55][56] Question: What is the timeline for BMN 333 and its potential indications? - BMN 333 is in a Phase I study, with plans for pivotal studies in 2027, and the company is evaluating its future role in additional indications [84] Question: How have U.S. versus ex-U.S. sales evolved for Voxzogo? - Approximately 75% of Voxzogo revenues come from outside the U.S., and this split is expected to fluctuate as the brand matures [88]